ArticleFrontiers in genetics2017
Breast Cancer Risk Estimation and Personal Insurance: A Qualitative Study Presenting Perspectives from Canadian Patients and Decision Makers.
Article in Frontiers in genetics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- "For and against" factors influencing participation in personalized breast cancer screening programs: a qualitative systematic review until March 2022.Archives of public health = Archives belges de sante publique · 2024Pooled it
- Genetic discrimination in insurance and employment based on personalized risk stratification for breast cancer screening.Frontiers in genetics · 2025Article
- Do women with a history of breast cancer recommend risk-based breast cancer screening? An in-depth interview study.Frontiers in psychology · 2025Article
- On the determinants and the role of the payers in the uptake of genetic testing and data sharing in personalized health.Frontiers in public health · 2023Article
- Article
- Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.Journal of personalized medicine · 2021Article
- Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I).Journal of personalized medicine · 2021Article
- Putting the Patient First: A Scoping Review of Patient Desires in Canada.Healthcare policy = Politiques de sante · 2021Article
- MicroRNA-216b targetsInternational journal of biological sciences · 2021Article
- Establishing the International Genetic Discrimination Observatory.Nature genetics · 2020Article
- Envisioning Implementation of a Personalized Approach in Breast Cancer Screening Programs: Stakeholder Perspectives.Healthcare policy = Politiques de sante · 2019Article
- Genetic testing, insurance discrimination and medical research: what the United States can learn from peer countries.Nature medicine · 2019Review
- Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.Journal of medical genetics · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Genetic stratification approaches in personalized medicine may considerably improve our ability to predict breast cancer risk for women at higher risk of developing breast cancer. Notwithstanding these advantages, concerns have been raised about the use of the genetic information derived in these processes, outside of the research and medical health care settings, by third parties such as insurers. Indeed, insurance applicants are asked to consent to insurers accessing their medical information (implicitly including genetic) to verify or determine their insurability level, or eligibility to certain insurance products. This use of genetic information may result in the differential treatment of individuals based on their genetic information, which could lead to higher premium, exclusionary clauses or even the denial of coverage. This phenomenon has been commonly referred to as "Genetic Discrimination" (GD). In the Canadian context, where federal Bill S-201,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.